R
Revolution Medicines
On Target to Outsmart Cancer
About Revolution Medicines
Revolution Medicines is a clinical-stage precision oncology company that discovers, develops, and delivers novel targeted therapies for patients with RAS-addicted cancers. Its R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, developed using a tri-complex inhibitor platform that targets the active form of oncogenic RAS.
Industry
Biotechnology / precision oncology (drug discovery and development)
Headquarters
Redwood City, California, USA
Company size
883 employees (as of December 31, 2025)
Founded
2014
What we do
RAS(ON) inhibitorsTargeted oncology therapeuticsRAS-addicted cancersTri-complex inhibitor platformSmall-molecule drug discovery
Interested in Revolution Medicines?
Join our talent pool to be considered for future opportunities.